ABSTRACT

**Background:** Insulin resistance is present in 50% or more of patients with primary hypothyroidism. Metformin can decrease TSH levels in these patients by a complex matter, this can be of great help in clinical practice.

**Objective:** This study was designed to evaluate the effect of metformin in reducing TSH levels in patients with primary hypothyroidism.

**Methods:** Hundred patients with primary hypothyroidism, 82 females, 18 males were included in this study, everyone was followed up for two months after adding metformin 850 mg twice daily in addition to thyroxin.

**Results:** 36 patients (36%) have a normal baseline TSH and no change after 2 months, 64 patients (64%) have a change in TSH either a decrease (49 patients, 79.56%) or an increase (15 patients, 23.44%).

**Conclusion:** Metformin therapy is highly effective in reducing TSH levels in patients with primary hypothyroidism.

**Keywords:** Primary hypothyroidism, insulin resistance, metformin.

INTRODUCTION

Insulin resistance (IR) for several decades was known, and till now, to be linked to type 2 diabetes and later on to metabolic syndrome as a whole.

It is said to be due to impaired biological and physiological responses to insulin in the target tissues. It is a strong independent risk factor for type 2 diabetes with all its sequelae (1,2).

Several years ago an association between IR and primary hypothyroidism was found in some studies and IR was present in 57.2% in one of these studies, compared to 5.8% in healthy individuals, without any detectable endocrine problem (3).

In another study carbimazole was given to experimental rats to induce hypothyroidism, in which IR started to rise when hypothyroidism was evident which was associated with a rise in the levels of some inflammatory markers, such as interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and others (4).

Also a positive correlation between TSH and HOMA-IR score was found in patients with primary hypothyroidism (5,6).

Some other studies had shown that IR occurs in hypothyroid patients due to defects in the ability of insulin to increase the glucose utilization in the peripheral tissues, this could justify the increased risk of IR associated disorders, like cardiovascular disease (9).

The last mentioned problem was found to be associated with altered endothelial function, even in hypothyroid patients who were rendered euthyroid with thyroxin (10).

These cardiovascular problems were found to increase even in patients with subclinical hypothyroidism (11,12).

Hypothyroidism is said to be a risk factor for the development of type 2 diabetes, stressing the role of IR in these patients (13-15).

A question could be logically asked, depending on these information, is it possible to reduce TSH levels in patients with primary hypothyroidism by reducing IR with metformin?.

From time to time endocrinologists are faced with hypothyroid patients who require high doses of thyroxin to reduce their TSH levels, for e.g. 300 mcg, 400 mcg or even more. However, their TSH levels still remain high.

From this aspect, we performed our study using metformin, hoping that by reducing IR (may be by another mechanism) we could reduce TSH levels in these patients.
**METHODS**

This interventional, prospective study was performed in the Specialized Center for Endocrinology and Diabetes, Baghdad from May till November 2017. It included 100 patients with primary hypothyroidism, 82 females and 18 males, all were on thyroxin therapy. Patients consent was taken from each one. None of them has any evident other endocrine problem. Initial T4 and TSH were measured for each patient and repeated after adding metformin 850 mg twice daily for two months. Five milliliters of blood were aspirated from each patient for estimation of T4 and TSH , initially and after 2 months, and sent to the Lab. for analysis , in which the COBAS method was used.

Thyroxin dosage was kept the same during the study period. The lab. normal reference range for TSH was 0.25-5 miu/ml. Measurement of height and weight was done to all patients at the start and weight measurement was repeated after two months of metformin therapy.

**RESULTS**

Table (1) shows the demographic data in addition to TSH levels pre and post-metformin therapy, also the weight initially, and after 2 months, there was a significant change in TSH and weight after 2 months (P<0.05).

Figure (1) shows the mean TSH before and after metformin for the whole 100 patients, TSH1 for baseline TSH and TSH2 for TSH level after 2 months. Mean TSH1 was 4.4 while mean TSH2 was 2.8 (p=0.006).

Figure (2) shows the different causes of hypothyroidism in the total number of patients, 70% auto-immune, 23% post-thyroidectomy, 5% post-radioactive iodine therapy (post-RAI), and 2% congenital.

Table (2) shows the TSH status after 2 months of metformin therapy, and as it is shown in the table, 36% have normal initial TSH and remained normal after 2 months, 64% showed a change in TSH (decreased in 49 patients =76.56%, increased in 15 patients =23.44%).

Further details are shown in table (3) where 40 patients have high TSH1, that decreased after metformin, 9 patients have normal TSH1 that decreased after metformin.

In those 40 patients with high TSH1, table (4) shows the mean TSH as 24.56 miu/ml, while mean TSH2 was 4.4 miu/ml, with a percent reduction of 65.68% (p<0.05).

More details can be found in table (5) where 17 out of 40 showed >90% reduction in TSH after metformin & 23 showed <90% reduction.

Table (6) shows that among these 40 patients 17 had a mean percent reduction in TSH of 95.9%, 11 patients showed 64.62% reduction, while 12 patients showed 23.76% reduction.

Table (7) shows the details of 9 patients with normal TSH1 that decreased with metformin, 3 patients showed 98.98% reduction, 6 showed 62.01% reduction.

Table (8) shows the change in weight in 40 patients with high TSH1 and lower TSH2 after metformin, with a mean decrease in weight of 2.1 kg (3.26% reduction).

The mean weight reduction in 9 patients with normal TSH1 and reduced TSH2 was 1.75 kg (2% reduction) as shown in table (9).

Table (10) shows the mean TSH1(9.8) and TSH2 (19.28 miu/ml) in those 15 patients who showed an increase in TSH after metformin.

Table (11) shows the mean difference in weight (0.4 kg decrease after 2 months) in this last group.

Table (12) shows the details of 7 patients (7%) who showed resistance to exogenous thyroxin.
Table 1: shows the demographic data with the change in TSH and weight before and after metformin therapy in the total 100 patients.

<table>
<thead>
<tr>
<th>Group (people) N=100</th>
<th>MEAN</th>
<th>SD</th>
<th>SE</th>
<th>MEDIAN</th>
<th>RANGE</th>
<th>PERCENTAGE %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender Women/Men (N[%])</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>82 (82%)/18 (18%)</td>
</tr>
<tr>
<td>Age(year)</td>
<td>45.28</td>
<td>11.8</td>
<td>1.176</td>
<td>45</td>
<td>15-77</td>
<td></td>
</tr>
<tr>
<td>Weight (Pre-treatment)KG</td>
<td>80.4</td>
<td>17.0</td>
<td>1.69</td>
<td>80.5</td>
<td>45-130</td>
<td></td>
</tr>
<tr>
<td>Weight(Post-treatment)KG</td>
<td>79.2</td>
<td>17.0</td>
<td>1.689</td>
<td>79</td>
<td>45-130</td>
<td></td>
</tr>
<tr>
<td>*TSH (Pre-treatment)µU/MI</td>
<td>12.1</td>
<td>16.6</td>
<td>1.66</td>
<td>4.4</td>
<td>0.2-60</td>
<td></td>
</tr>
<tr>
<td>*TSH (Post-treatment) µU/MI</td>
<td>6.59</td>
<td>11.35</td>
<td>1.13</td>
<td>2.8</td>
<td>0.05-60</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>28%</td>
</tr>
</tbody>
</table>

P<0.05 using Wilcoxon signed ranks test*

Figure 1: shows median TSH status after metformin in the total 100 patients. TSH 1 indicates initial TSH and TSH 2 indicate level after metformin. (P value =0.006 using Wilcoxon signed ranks test)
The Role of Metformin …

Khalid I Al-Lehibi .. et al

Figure 2: Different causes of primary hypothyroidism in the study patients N=100.

<table>
<thead>
<tr>
<th>TSH status after Metformin N=100</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal TSH</td>
<td>36%</td>
</tr>
<tr>
<td>Abnormal TSH</td>
<td>64%</td>
</tr>
<tr>
<td>Decreased</td>
<td>76.56%</td>
</tr>
<tr>
<td>Increased</td>
<td>23.44%</td>
</tr>
</tbody>
</table>

Table 2: summarize the TSH status after treatment with Metformin in the total 100 patients.

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>TSH1</th>
<th>TSH2</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>40</td>
<td>Increased</td>
<td>Decreased</td>
</tr>
<tr>
<td>9</td>
<td>Normal</td>
<td>Decreased</td>
</tr>
<tr>
<td>15</td>
<td>Increased</td>
<td>Increased</td>
</tr>
</tbody>
</table>

Table 3: shows TSH status after metformin in the total 100 patients. TSH1 indicates initial TSH, TSH 2 indicates TSH level after therapy with metformin.

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Mean TSH 1</th>
<th>Mean TSH 2</th>
<th>Mean decrease</th>
<th>percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>24.56</td>
<td>4.4</td>
<td>65.68</td>
<td></td>
</tr>
</tbody>
</table>

Table 4: shows mean TSH before and after metformin P<0.05 using Wilcoxon signed ranks test.

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>% of decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>More than 90%</td>
</tr>
<tr>
<td>23</td>
<td>Less</td>
</tr>
</tbody>
</table>

Table 5: shows the percent TSH decrease after 2 months of metformin therapy in 40 patients with high initial TSH.

<table>
<thead>
<tr>
<th>% of reduction</th>
<th>Mean % of reduction</th>
<th>% of reduction</th>
<th>Number of patients</th>
<th>Mean TSH1</th>
<th>Mean TSH2</th>
</tr>
</thead>
<tbody>
<tr>
<td>More than 90%</td>
<td>95.9</td>
<td>17</td>
<td>35.3</td>
<td>1.24</td>
<td></td>
</tr>
<tr>
<td>50-90</td>
<td>64.62</td>
<td>11</td>
<td>22</td>
<td>7.28</td>
<td></td>
</tr>
<tr>
<td>Less than 50%</td>
<td>23.76</td>
<td>12</td>
<td>8.4</td>
<td>6.25</td>
<td></td>
</tr>
</tbody>
</table>

Table 6: TSH status after metformin and percentage of reduction.

<table>
<thead>
<tr>
<th>% of reduction</th>
<th>Mean % of reduction</th>
<th>% of reduction</th>
<th>Number of patients</th>
<th>Mean TSH1</th>
<th>Mean TSH2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 90%</td>
<td>98.98</td>
<td>3</td>
<td>3.23</td>
<td>0.067</td>
<td></td>
</tr>
<tr>
<td>50-90</td>
<td>62.01</td>
<td>6</td>
<td>1.733</td>
<td>0.633</td>
<td></td>
</tr>
</tbody>
</table>

Table 7: shows the details of 9 patients with normal TSH1 and ≥ 50% reduction in TSH after metformin therapy.

| Weight status | Number of patients | Mean W1 | Mean W2 | Mean % of reduction | % of reduction of |%
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>decreased</td>
<td>23</td>
<td>78.9</td>
<td>76.3</td>
<td>2.1</td>
<td>3.26</td>
</tr>
<tr>
<td>No change</td>
<td>12</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>increased</td>
<td>5</td>
<td>83.6</td>
<td>88.1</td>
<td>2.5</td>
<td>2.91</td>
</tr>
</tbody>
</table>
Table 8: shows the weight status in 40 patients with high initial TSH who their TSH level decreased after metformin. (W 1 =initial weight, W 2= weight after metformin).

<table>
<thead>
<tr>
<th>Weight status</th>
<th>Number of patients</th>
<th>Mean W1</th>
<th>Mean W2</th>
<th>Mean change</th>
<th>% of reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>decreased</td>
<td>4</td>
<td>81.5</td>
<td>79.75</td>
<td>1.75</td>
<td>2</td>
</tr>
<tr>
<td>No change</td>
<td>3</td>
<td>---------</td>
<td>---------</td>
<td>-------------</td>
<td>----------------</td>
</tr>
<tr>
<td>increased</td>
<td>2</td>
<td>58.5</td>
<td>59.25</td>
<td>0.75</td>
<td>1.34</td>
</tr>
</tbody>
</table>

Table 9: shows the weight status in patients with TSH2 decrease after metformin for a normal TSH1. (W 1 =initial weight, W 2= weight after metformin).

<table>
<thead>
<tr>
<th>TSH 1</th>
<th>TSH 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.8</td>
<td>19.28</td>
</tr>
</tbody>
</table>

Table 10: shows the TSH status after metformin in 15 patients with increase in the TSH after 2 months.

<table>
<thead>
<tr>
<th>Mean W1</th>
<th>Mean W2</th>
<th>Mean change</th>
</tr>
</thead>
<tbody>
<tr>
<td>87.9</td>
<td>87.5</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Table 11: shows the weight status in 15 patients with increase in the TSH after 2 months.(W 1 =initial weight, W 2= weight after metformin).

<table>
<thead>
<tr>
<th>Thyroxin dose (µg)</th>
<th>Weight (Kg)</th>
<th>Thyroxin dose (µg/Kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>200</td>
<td>55</td>
<td>3.6</td>
</tr>
<tr>
<td>150</td>
<td>65</td>
<td>2.3</td>
</tr>
<tr>
<td>300</td>
<td>68</td>
<td>6.25</td>
</tr>
<tr>
<td>150</td>
<td>63</td>
<td>2.38</td>
</tr>
<tr>
<td>200</td>
<td>85</td>
<td>2.35</td>
</tr>
<tr>
<td>150</td>
<td>45</td>
<td>3.34</td>
</tr>
<tr>
<td>200</td>
<td>90</td>
<td>2.2</td>
</tr>
</tbody>
</table>

Table 12: shows the dosage of thyroxin /kg/day needed to normalize TSH.

DISCUSSION

From this study we can see the TSH-lowering effect of metformin in patients with primary hypothyroidism. Out of 100 patients who were included in this study, 36 patients (36% ) had a normal initial TSH and showed no change with metformin therapy, while 64 patients (64%) showed a change in TSH, either a decrease (49 patients, 76.56%)or an increase (15 patients, 23.44%). We believe that , the last group of patients either did not take metformin, or thyroxin, or both , or there might be another unknown mechanism to explain such a rise in TSH as it will be discussed later.

In the whole 100 patients, mean TSH1(initial TSH) was 4.4,mean TSH2 (TSH after 2 months of metformin therapy) was 2.8 (P=0.006) as shown in figure (1). In 40 patients with high TSH1 (mean 24.56), there was a significant reduction in the mean TSH2 (4.4) after metformin (P<0.05) as shown in table (4). The TSH lowering effect of metformin cannot just be explained in the basis that it reduces IR , because we have noticed a number of patients with primary hypothyroidism who tried to reduce their weight by dieting and exercise, yet their TSH was not changed . while we know that these measures reduce IR ,this gives an idea that metformin ,by reducing IR, it also stimulates another pathway which helps to strengthen the action of exogenously given thyroxin. This is probably by increasing its action on the receptors in target tissues and in the pituitary itself. This is our explanation.
The Role of Metformin …

Khalid I Al-Lehibi .. et al

www.jkmc.uobaghdad.edu.iq

84 Al-Kindy College Medical Journal 2019:15 No.1

otherwise , we did not come across an explanation in the literature.
A number of studies had showed the TSH-
lowering effect of metformin in patients
with primary hypothyroidism who were
diabetic and were already on metformin
therapy (16,17).
In one of the studies, there was a 55% 
reduction in TSH after metformin ( Jean-
Pascal F ) (18).
In some studies, a hypothesis was given to 
explain the mode of action of metformin
in hypothyroid patients saying that it 
involves the action of metformin on 5-
AMP activated protein kinase (AMPK),
and in the liver, metformin suppresses 
gluconeogenesis by activating AMPK
(19,20).
In our study we found an evident 
reduction in weight in those patients who 
showed a reduction in TSH(mean 
reduction was 2-1 kg(3.26%)in 23 patients 
out of 40 with high mean TSH).
This cannot be related solely to metformin ,as it is weight neutral ,but mostly because 
it enhances the effect of exogenous 
thyroxin leading to an increased metabolic 
rate.
Those 15 patients who had an increase in 
TSH after metformin showed a minimal 
change in weight (0.4 kg).
Primary hypothyroidism is said to be 
refractory to exogenous thyroxin when 
there is a biochemical or clinical 
evidence of hypothyroidism i.e. serum 
TSH above the normal range following a 
6-weeks interval after the dose was last 
increased and/or unresolved symptoms of 
hypothyroidism despite increasing the 
dose of thyroxin beyond 1.9 microgram / 
kg/day (21).
In our study , 7 patients ( 7%) required > 
1.9 mic./kg/day to normalize their TSH 
levels , as it is shown in table 12. This is 
much lower than the results obtained by 
Vaisman , in Brazil , who found that 
resistance to exogenous thyroxin was 
present in 28% out of 2292 patients (22 ).
This difference is most probably because 
he studied a larger number of patients than 
we did.
This resistance is said to be due to either 
patient non-compliance, or the presence of 
mal-absorption or other causes(23 ).This 
can applied to those patients who showed 
an increase in TSH after 2 months of 
metformin therapy.

CONCLUSION

In this study there was a significant 
reduction in TSH in patients with primary 
hypothyroidism after 2 months of 
metformin therapy, there was also an 
evident reduction in weight, mostly due to 
the enhancing effect of metformin on 
exogenous thyroxin therapy. This effect of 
metformin can solve most of the problems 
associated with the need for high doses of 
thyroxin in some patients with primary 
hypothyroidism who seem to be resistant 
to the action of thyroxin. We have to 
declare that this effect of metformin 
should be observed carefully in patients 
with cardiovascular problems, because 
metformin might lead to a reduction 
of TSH below the acceptable levels 
leading to tachycardia and dysrrhythmia 
that might precipitate cardiovascular events 
in susceptible patients.

REFERENCES

resistance?. Heart Metab.2006; 30:30-34.
2. Badri NW.et al. Insulin Resistance improves 
more in women than in men in association 
with a weight loss intervention .J Obes weight 
Loss Ther 2018, 8:1.
3. Razaq SH, Allehibi K,Alwachi S. Insulin 
resistance in hypothyroid patients.Baghad 
4.Razaq 5H,Allehibi K ,Alwachi S. 
Comparison study for the effect of Interleukin-
6 and Carbimazole Drug in Rat Thyroid Gland 
5. Razaq SH, Allehibi K,Alwachi S. 
evaluation of some inflammatory markers in 
hypothyroid resistant patients . Baghdad 
hormone on adipose inflammation and insulin 
sensitivity of obese Wistar rats. Physiol Rep 
of pre-diabetes in hypothyroid patients. Intern 
8. Manju C,Madhur G, Suresh C. Correlation 
between insulin resistance and homocysteine in 
hypothyroid patients. JKILMSU; 7:75-81.